RP-HPLC method development and validation for simultaneous estimation of telmisartan, rosuvastatin calcium, and
Rujuta P Mistry1, Chainesh Shah2, Rakesh Jat3
1Shri Jagdishprasad Jhabarmal Tibrewala University, Vidyanagari, India.
Introduction:
Dyslipidemia-hypertension proves to be a major risk factor for cardiovascular diseases. In order to achieve better adherence and cost-effectiveness than free equivalent combination therapies, a fixed-dose combination therapy with telmisartan (TEL), rosuvastatin calcium (ROS) and amlodipine besylate (AML) is required in this type of patients.
More Related Videos
07:29HPLC Coupled with Chemical Fingerprinting for Multi-Pattern Recognition for Identifying the Authenticity of Clematidis Armandii Caulis
Published on: November 11, 2022
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018